Biotinylated Human IL13RA2 Protein (C-Fc-Avi)

Product Details


ApplicationELISA, BLI
FormatLiquid, Biotinylated
Expression HostCHO
Target NameIL13RA2, CD213A2, IL-13R, IL13BP
SpeciesHuman
SourcesRecombinant Human IL13RA2 protein (Cys22-Leu342) with C-terminus Fc-Avi tag is expressed in CHO cells. This protein was site-specifically labeled with Biotin by BirA ligase.
accession numberQ14627
Molecular WeightThe protein has a predicted molecular weight of 65.7 kDa. Under DTT-reducing conditions, it migrates at approximately 65-80 kDa on SDS-PAGE.
Affinity TagC-Fc-Avi
Purity>95% based on SDS-PAGE under reducing condition
Formulation1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin levelNot tested
Protein Concentration25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and HandlingBriefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

Background Information


CD213A2, also known as IL13Rα2, is a type I transmembrane protein belonging to the hematopoietin receptor family. It binds interleukin-13 (IL-13) with high affinity but lacks a functional cytoplasmic signaling domain, suggesting that it primarily acts as a decoy receptor, antagonizing IL-13 signaling mediated by the IL-13Rα1/IL-4Rα complex. IL13Rα2 is expressed in fibroblasts, smooth muscle cells, keratinocytes, and activated B cells, though its surface expression is tightly regulated and much of it resides intracellularly or in soluble form. In addition to inhibiting IL-13 activity, IL13Rα2 has been reported to suppress IL-4 signaling via physical interaction with IL-4Rα, while paradoxically promoting TGF-β production and fibrosis. Importantly, IL13Rα2 is highly and specifically overexpressed in certain cancers, such as glioblastoma multiforme and high-grade astrocytomas, making it a promising target for tumor-specific immunotherapies and viral vector-mediated gene delivery approaches.